Evidence map›Paper›PMID 39422765›Full record

Trial reportEuropean heart journal. Acute cardiovascular care2024

Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial.

Philip Leissner, Katarina Mars, Sophia Humphries, Patric Karlström, Troels Yndigegn, Tomas Jernberg, Robin Hofmann, Claes Held, Erik M G Olsson

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal. Acute cardiovascular care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Philip LeissnerDepartment of Women's and Children's Health, Uppsala University, MTC-huset, Dag Hammarskjölds väg 14B, Akademiska sjukhuset, 752 37 Uppsala, Sweden.ORCID 0000-0003-0787-9102
Katarina MarsDepartment of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.ORCID 0000-0002-6739-1558
Sophia HumphriesDepartment of Women's and Children's Health, Uppsala University, MTC-huset, Dag Hammarskjölds väg 14B, Akademiska sjukhuset, 752 37 Uppsala, Sweden.ORCID 0000-0002-3680-6351
Patric KarlströmDepartment of Internal Medicine, Ryhov County Hospital, Jönköping, Sweden.ORCID 0000-0002-2441-0245
Troels YndigegnDepartment of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.ORCID 0000-0002-8960-2125
Tomas JernbergDepartment Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1695-379X
Robin HofmannDepartment of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.ORCID 0000-0002-8907-895X
Claes HeldDepartment of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-9402-7404
Erik M G OlssonDepartment of Women's and Children's Health, Uppsala University, MTC-huset, Dag Hammarskjölds väg 14B, Akademiska sjukhuset, 752 37 Uppsala, Sweden.ORCID 0000-0002-1591-7407

Funding

Region Stockholm 2018-0490Swedish Heart and Lung AssociationSwedish Heart-Lung Foundation 20210216Swedish Research Council to the U-CARE strategic research environment
6 · The paper itself

Abstract

aimsAmong patients with myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI trial did not demonstrate a benefit of beta-blocker vs. no beta-blocker treatment on all-cause mortality and recurrent myocardial infarction. The aim of this pre-specified sub-study was to investigate effects of beta-blockers on self-reported symptoms of anxiety and depression. METHODS AND

resultsIn this parallel-group, open-label, registry-based randomized trial, assessments with the Hospital Anxiety and Depression Scale were obtained at hospitalization and two follow-up points (6-10 weeks and 12-14 months) after MI. Analyses were based on the intention-to-treat principle using linear mixed models, calculating both short- and long-term effects. From August 2018 through June 2022, 806 patients were enrolled. At baseline, 27% of patients were possible cases of anxiety (m, 5.6; SD, 3.9) and 14% were possible cases of depression (m, 3.9; SD, 3.2). Beta-blocker treatment had a negative effect on depressive symptoms at both follow-ups 1 (β = 0.48; 95% CI 09-0.86; P = 0.015) and 2 (β = 0.41; 95% CI = 0.01-0.81; P = 0.047), but no effect on anxiety.

conclusionBeta-blocker treatment led to a modest increase in depressive symptoms among MI patients with preserved LVEF. This observed effect was most pronounced in individuals with prior beta-blocker treatment. In routine initiation and continuation of beta-blocker treatment, a risk of slightly increased depressive symptoms should be considered.

Indexed as

Adrenergic beta-AntagonistsAnxietyDepressionMyocardial InfarctionQuality of LifeVentricular Function, LeftAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedStroke VolumeTime FactorsTreatment OutcomeAdrenergic beta-AntagonistsAnxietyBeta-blockerDepressionLinear mixed modelsPsychological distressTreatment

Identifiers

PMID39422765
PMCPMC11638855

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.